Selected research
Market Structure
Global Depression Treatment Device Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Depression Treatment Device market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for Depression Treatment Device is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Depression Treatment Device is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Depression Treatment Device is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Depression Treatment Device is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Depression Treatment Device include Alpha-Stim, BrainsWay, Caputron Medical, Electromedical Products International, Inc., Fisher Wallace Laboratories, Flow Neuroscience, Flow Neuroscience AB, Ginger and INNOVATIVE NEUROLOGICAL Devices LLC, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Depression Treatment Device market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Depression Treatment Device and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Depression Treatment Device sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Depression Treatment Device market size, projected growth trends, production technologies, key applications, and end-use industries.
Depression Treatment Device Segment by Company
Alpha-Stim
BrainsWay
Caputron Medical
Electromedical Products International, Inc.
Fisher Wallace Laboratories
Flow Neuroscience
Flow Neuroscience AB
Ginger
INNOVATIVE NEUROLOGICAL Devices LLC
Magnus Medical
Neurolief
Neuronetics
NeuroStar
The Magstim Company Limited
Depression Treatment Device Segment by Type
Transcranial Direct Current Stimulation (tDCS)
Transcranial Random Noise Stimulation (tRNS)
Transcranial Pulsed Current Stimulation (tPCS)
Transcranial Alternating Current Stimulation (tACS)
Electroconvulsive therapy (ECT)
Others
Depression Treatment Device Segment by Application
Hospital
Clinic
Others
Depression Treatment Device Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Depression Treatment Device market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Depression Treatment Device and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Depression Treatment Device.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Depression Treatment Device market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Depression Treatment Device manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Depression Treatment Device in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Depression Treatment Device in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Transcranial Direct Current Stimulation (tDCS)
- Transcranial Random Noise Stimulation (tRNS)
- Transcranial Pulsed Current Stimulation (tPCS)
- Transcranial Alternating Current Stimulation (tACS)
- Electroconvulsive therapy (ECT)
- Others
Applications
- Hospital
- Clinic
- Others
Companies covered
- Alpha-Stim
- BrainsWay
- Caputron Medical
- Electromedical Products International, Inc.
- Fisher Wallace Laboratories
- Flow Neuroscience
- Flow Neuroscience AB
- Ginger
- INNOVATIVE NEUROLOGICAL Devices LLC
- Magnus Medical
- Neurolief
- Neuronetics
- NeuroStar
- The Magstim Company Limited
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Depression Treatment Device Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Depression Treatment Device Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Depression Treatment Device Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Depression Treatment Device Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Depression Treatment Device Market Dynamics
- 2.1 Depression Treatment Device Industry Trends
- 2.2 Depression Treatment Device Industry Drivers
- 2.3 Depression Treatment Device Industry Opportunities and Challenges
- 2.4 Depression Treatment Device Industry Restraints
3 Depression Treatment Device Market by Manufacturers
- 3.1 Global Depression Treatment Device Revenue by Manufacturers (2021-2026)
- 3.2 Global Depression Treatment Device Sales by Manufacturers (2021-2026)
- 3.3 Global Depression Treatment Device Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Depression Treatment Device Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Depression Treatment Device Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Depression Treatment Device Manufacturers, Product Type & Application
- 3.7 Global Depression Treatment Device Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Depression Treatment Device Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Depression Treatment Device Players Market Share by Revenue in 2025
- 3.8.3 2025 Depression Treatment Device Tier 1, Tier 2, and Tier 3
4 Depression Treatment Device Market by Type
- 4.1 Depression Treatment Device Type Introduction
- 4.1.1 Transcranial Direct Current Stimulation (tDCS)
- 4.1.2 Transcranial Random Noise Stimulation (tRNS)
- 4.1.3 Transcranial Pulsed Current Stimulation (tPCS)
- 4.1.4 Transcranial Alternating Current Stimulation (tACS)
- 4.1.5 Electroconvulsive therapy (ECT)
- 4.1.6 Others
- 4.2 Global Depression Treatment Device Sales by Type
- 4.2.1 Global Depression Treatment Device Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Depression Treatment Device Sales by Type (2021-2032)
- 4.2.3 Global Depression Treatment Device Sales Market Share by Type (2021-2032)
- 4.3 Global Depression Treatment Device Revenue by Type
- 4.3.1 Global Depression Treatment Device Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Depression Treatment Device Revenue by Type (2021-2032)
- 4.3.3 Global Depression Treatment Device Revenue Market Share by Type (2021-2032)
5 Depression Treatment Device Market by Application
- 5.1 Depression Treatment Device Application Introduction
- 5.1.1 Hospital
- 5.1.2 Clinic
- 5.1.3 Others
- 5.2 Global Depression Treatment Device Sales by Application
- 5.2.1 Global Depression Treatment Device Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Depression Treatment Device Sales by Application (2021-2032)
- 5.2.3 Global Depression Treatment Device Sales Market Share by Application (2021-2032)
- 5.3 Global Depression Treatment Device Revenue by Application
- 5.3.1 Global Depression Treatment Device Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Depression Treatment Device Revenue by Application (2021-2032)
- 5.3.3 Global Depression Treatment Device Revenue Market Share by Application (2021-2032)
6 Global Depression Treatment Device Sales by Region
- 6.1 Global Depression Treatment Device Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Depression Treatment Device Sales by Region (2021-2032)
- 6.2.1 Global Depression Treatment Device Sales by Region (2021-2026)
- 6.2.2 Global Depression Treatment Device Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Depression Treatment Device Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Depression Treatment Device Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Depression Treatment Device Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Depression Treatment Device Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Depression Treatment Device Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Depression Treatment Device Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Depression Treatment Device Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Depression Treatment Device Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Depression Treatment Device Revenue by Region
- 7.1 Global Depression Treatment Device Revenue by Region
- 7.1.1 Global Depression Treatment Device Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Depression Treatment Device Revenue by Region (2021-2026)
- 7.1.3 Global Depression Treatment Device Revenue by Region (2027-2032)
- 7.1.4 Global Depression Treatment Device Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Depression Treatment Device Revenue (2021-2032)
- 7.2.2 North America Depression Treatment Device Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Depression Treatment Device Revenue (2021-2032)
- 7.3.2 Europe Depression Treatment Device Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Depression Treatment Device Revenue (2021-2032)
- 7.4.2 Asia-Pacific Depression Treatment Device Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Depression Treatment Device Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Depression Treatment Device Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 Alpha-Stim
- 8.1.1 Alpha-Stim Company Information
- 8.1.2 Alpha-Stim Business Overview
- 8.1.3 Alpha-Stim Depression Treatment Device Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 Alpha-Stim Depression Treatment Device Product Portfolio
- 8.1.5 Alpha-Stim Recent Developments
- 8.2 BrainsWay
- 8.2.1 BrainsWay Company Information
- 8.2.2 BrainsWay Business Overview
- 8.2.3 BrainsWay Depression Treatment Device Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 BrainsWay Depression Treatment Device Product Portfolio
- 8.2.5 BrainsWay Recent Developments
- 8.3 Caputron Medical
- 8.3.1 Caputron Medical Company Information
- 8.3.2 Caputron Medical Business Overview
- 8.3.3 Caputron Medical Depression Treatment Device Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 Caputron Medical Depression Treatment Device Product Portfolio
- 8.3.5 Caputron Medical Recent Developments
- 8.4 Electromedical Products International, Inc.
- 8.4.1 Electromedical Products International, Inc. Company Information
- 8.4.2 Electromedical Products International, Inc. Business Overview
- 8.4.3 Electromedical Products International, Inc. Depression Treatment Device Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 Electromedical Products International, Inc. Depression Treatment Device Product Portfolio
- 8.4.5 Electromedical Products International, Inc. Recent Developments
- 8.5 Fisher Wallace Laboratories
- 8.5.1 Fisher Wallace Laboratories Company Information
- 8.5.2 Fisher Wallace Laboratories Business Overview
- 8.5.3 Fisher Wallace Laboratories Depression Treatment Device Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.5.4 Fisher Wallace Laboratories Depression Treatment Device Product Portfolio
- 8.5.5 Fisher Wallace Laboratories Recent Developments
- 8.6 Flow Neuroscience
- 8.6.1 Flow Neuroscience Company Information
- 8.6.2 Flow Neuroscience Business Overview
- 8.6.3 Flow Neuroscience Depression Treatment Device Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.6.4 Flow Neuroscience Depression Treatment Device Product Portfolio
- 8.6.5 Flow Neuroscience Recent Developments
- 8.7 Flow Neuroscience AB
- 8.7.1 Flow Neuroscience AB Company Information
- 8.7.2 Flow Neuroscience AB Business Overview
- 8.7.3 Flow Neuroscience AB Depression Treatment Device Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.7.4 Flow Neuroscience AB Depression Treatment Device Product Portfolio
- 8.7.5 Flow Neuroscience AB Recent Developments
- 8.8 Ginger
- 8.8.1 Ginger Company Information
- 8.8.2 Ginger Business Overview
- 8.8.3 Ginger Depression Treatment Device Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.8.4 Ginger Depression Treatment Device Product Portfolio
- 8.8.5 Ginger Recent Developments
- 8.9 INNOVATIVE NEUROLOGICAL Devices LLC
- 8.9.1 INNOVATIVE NEUROLOGICAL Devices LLC Company Information
- 8.9.2 INNOVATIVE NEUROLOGICAL Devices LLC Business Overview
- 8.9.3 INNOVATIVE NEUROLOGICAL Devices LLC Depression Treatment Device Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.9.4 INNOVATIVE NEUROLOGICAL Devices LLC Depression Treatment Device Product Portfolio
- 8.9.5 INNOVATIVE NEUROLOGICAL Devices LLC Recent Developments
- 8.10 Magnus Medical
- 8.10.1 Magnus Medical Company Information
- 8.10.2 Magnus Medical Business Overview
- 8.10.3 Magnus Medical Depression Treatment Device Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.10.4 Magnus Medical Depression Treatment Device Product Portfolio
- 8.10.5 Magnus Medical Recent Developments
- 8.11 Neurolief
- 8.11.1 Neurolief Company Information
- 8.11.2 Neurolief Business Overview
- 8.11.3 Neurolief Depression Treatment Device Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.11.4 Neurolief Depression Treatment Device Product Portfolio
- 8.11.5 Neurolief Recent Developments
- 8.12 Neuronetics
- 8.12.1 Neuronetics Company Information
- 8.12.2 Neuronetics Business Overview
- 8.12.3 Neuronetics Depression Treatment Device Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.12.4 Neuronetics Depression Treatment Device Product Portfolio
- 8.12.5 Neuronetics Recent Developments
- 8.13 NeuroStar
- 8.13.1 NeuroStar Company Information
- 8.13.2 NeuroStar Business Overview
- 8.13.3 NeuroStar Depression Treatment Device Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.13.4 NeuroStar Depression Treatment Device Product Portfolio
- 8.13.5 NeuroStar Recent Developments
- 8.14 The Magstim Company Limited
- 8.14.1 The Magstim Company Limited Company Information
- 8.14.2 The Magstim Company Limited Business Overview
- 8.14.3 The Magstim Company Limited Depression Treatment Device Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.14.4 The Magstim Company Limited Depression Treatment Device Product Portfolio
- 8.14.5 The Magstim Company Limited Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Depression Treatment Device Value Chain Analysis
- 9.1.1 Depression Treatment Device Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Depression Treatment Device Production Mode & Process
- 9.2 Depression Treatment Device Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Depression Treatment Device Distributors
- 9.2.3 Depression Treatment Device Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst